294 related articles for article (PubMed ID: 22895656)
1. Adherence to adjuvant endocrine therapy in women with breast cancer.
Danilak M; Chambers CR
J Oncol Pharm Pract; 2013 Jun; 19(2):105-10. PubMed ID: 22895656
[TBL] [Abstract][Full Text] [Related]
2. Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study.
Wigertz A; Ahlgren J; Holmqvist M; Fornander T; Adolfsson J; Lindman H; Bergkvist L; Lambe M
Breast Cancer Res Treat; 2012 May; 133(1):367-73. PubMed ID: 22286315
[TBL] [Abstract][Full Text] [Related]
3. Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer.
Nekhlyudov L; Li L; Ross-Degnan D; Wagner AK
Breast Cancer Res Treat; 2011 Nov; 130(2):681-9. PubMed ID: 21842245
[TBL] [Abstract][Full Text] [Related]
4. Eligibility, compliance and persistence of sequential therapy with aromatase inhibitors following 2-3 years of tamoxifen in endocrine adjuvant breast cancer therapy.
Kilic N; Myrick ME; Schmid SM; Gueth U
Oncology; 2011; 81(3-4):151-7. PubMed ID: 22041855
[TBL] [Abstract][Full Text] [Related]
5. Adherence to endocrine therapy for breast cancer.
Chlebowski RT; Geller ML
Oncology; 2006; 71(1-2):1-9. PubMed ID: 17344666
[TBL] [Abstract][Full Text] [Related]
6. Endocrine therapy for early breast cancer.
Hussain SA; Williams S; Stevens A; Rea DW
Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
[TBL] [Abstract][Full Text] [Related]
7. Duration of adjuvant endocrine therapy of breast cancer: how much is enough?
Ward JH
Curr Opin Obstet Gynecol; 2010 Feb; 22(1):51-5. PubMed ID: 19952743
[TBL] [Abstract][Full Text] [Related]
8. Eligibility, compliance and persistence of extended adjuvant endocrine therapy for breast cancer.
Myrick ME; Schmid SM; Kilic N; Güth U
Acta Oncol; 2012 Feb; 51(2):247-53. PubMed ID: 21985132
[TBL] [Abstract][Full Text] [Related]
9. Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
Singh Ranger G
J Clin Pharm Ther; 2005 Aug; 30(4):313-7. PubMed ID: 15985044
[TBL] [Abstract][Full Text] [Related]
10. Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis.
van Herk-Sukel MP; van de Poll-Franse LV; Voogd AC; Nieuwenhuijzen GA; Coebergh JW; Herings RM
Breast Cancer Res Treat; 2010 Aug; 122(3):843-51. PubMed ID: 20058066
[TBL] [Abstract][Full Text] [Related]
11. [Current adjuvant endocrine treatment of breast cancer].
Dedes KJ; Gabriel N; Fink D
Gynakol Geburtshilfliche Rundsch; 2008; 48(3):130-7. PubMed ID: 18566529
[TBL] [Abstract][Full Text] [Related]
12. Informing women with breast cancer about endocrine therapy: effects on knowledge and adherence.
Heisig SR; Shedden-Mora MC; von Blanckenburg P; Schuricht F; Rief W; Albert US; Nestoriuc Y
Psychooncology; 2015 Feb; 24(2):130-7. PubMed ID: 24953538
[TBL] [Abstract][Full Text] [Related]
13. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
[TBL] [Abstract][Full Text] [Related]
14. Clinical consultations and investigations before and after discontinuation of endocrine therapy in women with primary breast cancer.
Lopez D; Kemp-Casey A; Saunders C; Roughead E; Boyle F; Bulsara M; Preen D
Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765859
[TBL] [Abstract][Full Text] [Related]
15. Adherence to long-term adjuvant hormonal therapy for breast cancer.
Gotay C; Dunn J
Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):709-15. PubMed ID: 22098287
[TBL] [Abstract][Full Text] [Related]
16. Adherence rates and correlates in long-term hormonal therapy.
Dunn J; Gotay C
Vitam Horm; 2013; 93():353-75. PubMed ID: 23810015
[TBL] [Abstract][Full Text] [Related]
17. Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer.
Schwartzberg LS; Cobb P; Senecal F; Henry D; Kulig K; Walker MS; Houts AC; Stepanski EJ
Breast; 2009 Apr; 18(2):78-83. PubMed ID: 19342237
[TBL] [Abstract][Full Text] [Related]
18. Adherence to Adjuvant Endocrine Therapy in Christchurch Women with Early Breast Cancer.
Robinson B; Dijkstra B; Davey V; Tomlinson S; Frampton C
Clin Oncol (R Coll Radiol); 2018 Jan; 30(1):e9-e15. PubMed ID: 29103853
[TBL] [Abstract][Full Text] [Related]
19. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
Buzdar A; Chlebowski R; Cuzick J; Duffy S; Forbes J; Jonat W; Ravdin P
Curr Med Res Opin; 2006 Aug; 22(8):1575-85. PubMed ID: 16870082
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant endocrine therapy in breast cancer.
Abrial C; Mouret-Reynier MA; Curé H; Feillel V; Leheurteur M; Lemery S; Le Bouëdec G; Durando X; Dauplat J; Chollet P
Breast; 2006 Feb; 15(1):9-19. PubMed ID: 16230013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]